323 Intriguingly, the first SIRT1 activator to capture widespread attention was resveratrol, which exerts its effects through several mechanisms (Table 1)
It is a naturally occurring copper peptide complex studied for extracellular matrix remodeling, collagen-related signaling, wound-healing models, and skin-aging research
TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
With more than 30 years of injectable experience, multiple sites authorised by major global regulators, and a strong track record in tech transfer and aseptic scaling, ROIS is built to support both current demands and future developments
Kommu, S., and P
10.3389/fphar.2023.1135952 186 SiddiquiM